Ajanta Pharma Ltd. (AJANTPHARM) News & Corporate Actions | Announcements, Board Meetings, Splits, Bonuses, Rights Issues

{ "main_header": { "sid": 178818, "name": "Ajanta Pharma", "stock_name": "Ajanta Pharma", "full_name": "Ajanta Pharma Ltd.", "name_url": "stocks-analysis/ajanta-pharma", "exchange": 0, "exchangecode": "", "primexch": 1, "country_id": 34, "currency": "INR", "cmp": "3,534.95", "chg": -31.2, "chgp": "-0.87%", "dir": -1, "prev_price": "3,566.15", "mcapval": "44,541.00 Cr", "mcap": "Mid Cap", "scripcode": 532331, "symbol": "AJANTPHARM", "ind_name": "Pharmaceuticals & Biotechnology", "ind_code": 4, "sector_id": 65, "indexname": "India SENSEX", "isin": "INE031B01049", "curr_date": "Sep 21, 03:30 PM", "curr_time": "17:50 PM", "last_traded_at": "Sep 21, 03:30 PM IST", "bse_nse_vol": "1.38 lacs", "exc_status": "Active", "traded_date": "Sep 21, 2026", "traded_date_str": "2026 09 21", "score": "", "scoreText": "", "Live": 0, "market_time": 0, "is_blur": 1, "is_blur_class": "blur-registerF-score-header", "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/ajanta-pharma-178818-0&utm_source=Spage_Header_Score", "mojoone": { "ismore": 0, "all_data": [] } }, "news": { "results": [ { "title": "Ajanta Pharma Ltd. is Rated Buy by MarketsMOJO", "link": "https://www.marketsmojo.com/news/stock-recommendation/ajanta-pharma-ltd-is-rated-buy-by-marketsmojo-4199676", "imagepath": "https://i.marketsmojo.com/newsimg/2026/9/AjantaPharmaLtd_mojoScore_4199676.png", "date": "2026-09-21 10:10:58", "description": "Ajanta Pharma Ltd. is rated Buy by MarketsMOJO, with this rating last updated on 09 September 2026. While the rating was revised on that date, the analysis and financial metrics presented here reflect the stock’s current position as of 21 September 2026, providing investors with the latest insights into the company’s performance and outlook." }, { "title": "Ajanta Pharma Gains 2.18%: Four Key Factors Driving the Week’s Momentum", "link": "https://www.marketsmojo.com/news/stocks-in-action/ajanta-pharma-gains-218-four-key-factors-driving-the-weeks-momentum-4191783", "imagepath": "", "date": "2026-09-12 17:07:22", "description": " <div class=\"article-news-new\">\n <div class=\"article-container\">\n\n<div class=\"article-content\">\n <div class=\"highlight-box\">\n <h3>Key Events This Week</h3>\n <p><strong>07 Sep:</strong> Downgrade to Hold amid mixed technical and valuation signals</p>\n <p><strong>07 Sep:</strong> Technical momentum shifts from bullish to mildly bullish</p>\n <p><strong>08 Sep:</strong> Technical momentum upgrades to bullish with strong returns</p>\n <p><strong>10 Sep:</strong> Upgrade to Buy following robust financial and technical performance</p>\n </div>\n\n <div class=\"stats-row\">\n <div class=\"stat-item\"><div class=\"stat-label\">Week Open</div><div class=\"stat-value\">Rs.3,464.45</div></div>\n <div class=\"stat-item\"><div class=\"stat-label\">Week C..." }, { "title": "Ajanta Pharma Upgraded to Buy on Strong Technical and Financial Performance", "link": "https://www.marketsmojo.com/news/stock-recommendation/ajanta-pharma-upgraded-to-buy-on-strong-technical-and-financial-performance-4188694", "imagepath": "https://i.marketsmojo.com/newsimg/2026/9/AjantaPharmaLtd_mojoScore_4188694.png", "date": "2026-09-10 08:08:53", "description": "Ajanta Pharma Ltd., a mid-cap player in the Pharmaceuticals & Biotechnology sector, has seen its investment rating upgraded from Hold to Buy by MarketsMOJO as of 09 Sep 2026. This upgrade reflects a comprehensive reassessment across four key parameters: Quality, Valuation, Financial Trend, and Technicals, driven by the company’s recent robust financial performance and improving technical indicators." }, { "title": "Ajanta Pharma Ltd. Technical Momentum Shifts to Bullish Amid Strong Returns", "link": "https://www.marketsmojo.com/news/stocks-in-action/ajanta-pharma-ltd-technical-momentum-shifts-to-bullish-amid-strong-returns-4185461", "imagepath": "https://i.marketsmojo.com/newsimg/2026/9/AjantaPharmaLtd_technicaldot_4185461.png", "date": "2026-09-08 08:00:49", "description": "Ajanta Pharma Ltd., a mid-cap player in the Pharmaceuticals & Biotechnology sector, has witnessed a notable shift in its technical momentum, moving from mildly bullish to a more confident bullish stance. This change is underscored by a combination of positive signals from key technical indicators such as MACD, moving averages, and Bollinger Bands, despite mixed short-term price returns relative to the broader Sensex index." }, { "title": "Ajanta Pharma Downgraded to Hold Amid Mixed Technical and Valuation Signals", "link": "https://www.marketsmojo.com/news/stock-recommendation/ajanta-pharma-downgraded-to-hold-amid-mixed-technical-and-valuation-signals-4184908", "imagepath": "https://i.marketsmojo.com/newsimg/2026/9/AjantaPharmaLtd_mojoScore_4184908.png", "date": "2026-09-07 08:07:16", "description": "Ajanta Pharma Ltd., a prominent player in the Pharmaceuticals & Biotechnology sector, has seen its investment rating downgraded from Buy to Hold as of 4 September 2026. This adjustment reflects a nuanced reassessment across four key parameters: quality, valuation, financial trend, and technical indicators. Despite strong recent financial results and long-term outperformance, evolving market dynamics and valuation pressures have tempered investor enthusiasm." }, { "title": "Ajanta Pharma Ltd. Technical Momentum Shifts Amid Mixed Market Signals", "link": "https://www.marketsmojo.com/news/stocks-in-action/ajanta-pharma-ltd-technical-momentum-shifts-amid-mixed-market-signals-4184397", "imagepath": "https://i.marketsmojo.com/newsimg/2026/9/AjantaPharmaLtd_technicaldot_4184397.png", "date": "2026-09-07 08:00:26", "description": "Ajanta Pharma Ltd., a mid-cap player in the Pharmaceuticals & Biotechnology sector, has experienced a subtle shift in its technical momentum, moving from a bullish to a mildly bullish stance. Despite a recent downgrade in its Mojo Grade from Buy to Hold, the stock continues to demonstrate resilience with strong long-term returns, though short-term indicators suggest caution for investors." }, { "title": "Ajanta Pharma Ltd. is Rated Hold by MarketsMOJO", "link": "https://www.marketsmojo.com/news/stock-recommendation/ajanta-pharma-ltd-is-rated-hold-by-marketsmojo-4183189", "imagepath": "https://i.marketsmojo.com/newsimg/2026/9/AjantaPharmaLtd_mojoScore_4183189.png", "date": "2026-09-05 10:10:16", "description": "Ajanta Pharma Ltd. is rated 'Hold' by MarketsMOJO, with this rating last updated on 04 September 2026. While the rating change occurred on that date, the analysis and financial metrics discussed here reflect the stock's current position as of 05 September 2026, providing investors with the most up-to-date view of the company’s performance and outlook." }, { "title": "Ajanta Pharma Ltd. is Rated Buy by MarketsMOJO", "link": "https://www.marketsmojo.com/news/stock-recommendation/ajanta-pharma-ltd-is-rated-buy-by-marketsmojo-4168526", "imagepath": "https://i.marketsmojo.com/newsimg/2026/8/AjantaPharmaLtd_mojoScore_4168526.png", "date": "2026-08-25 10:11:15", "description": "Ajanta Pharma Ltd. is rated 'Buy' by MarketsMOJO, with this rating last updated on 30 July 2026. However, the analysis and financial metrics presented here reflect the stock's current position as of 25 August 2026, providing investors with the most up-to-date insight into the company’s performance and outlook." }, { "title": "Ajanta Pharma Ltd: Valuation Shift Signals Price Attractiveness Amid Strong Returns", "link": "https://www.marketsmojo.com/news/stocks-in-action/ajanta-pharma-ltd-valuation-shift-signals-price-attractiveness-amid-strong-returns-4166336", "imagepath": "https://i.marketsmojo.com/newsimg/2026/8/AjantaPharmaLtd_valuationdot_4166336.png", "date": "2026-08-24 08:00:07", "description": "Ajanta Pharma Ltd., a prominent player in the Pharmaceuticals & Biotechnology sector, has recently undergone a notable shift in its valuation parameters, moving from a 'very expensive' to an 'expensive' rating. This change reflects evolving market perceptions amid robust financial performance and relative comparisons with peers, prompting investors to reassess the stock’s price attractiveness in the current mid-cap landscape." } ], "total": 696, "sid": "178818", "stock_news_url": "https://www.marketsmojo.com/news/ajanta-pharma-178818" }, "announcements": [ { "caption": "Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations 2011.", "datetime": "18-Sep-2026", "details": "The Exchange has received Disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations 2011 on September 18 2026 for Aayush Agrawal trustee Aayush Agrawal Trust", "source": "BSE" }, { "caption": "Announcement under Regulation 30 (LODR)-Newspaper Publication", "datetime": "31-Aug-2026", "details": "Pls find enclosed newspaper publication for transfer of equity shares to IEPF.", "source": "BSE" }, { "caption": "Participation In Investor Conference", "datetime": "31-Aug-2026", "details": "Pls find enclosed Intimation w.r.t Participation in Investor Conference.", "source": "BSE" } ], "corporate_actions": [ { "img": "board-meeting.svg", "title": "BOARD MEETING", "msg": "<span>No</span> Upcoming Board Meetings", "data": [] }, { "img": "dividend.svg", "title": "DIVIDEND", "msg": "", "data": [ { "txt": "Ajanta Pharma Ltd. has declared <strong>1600%</strong> dividend, ex-date: 05 Aug 26", "dt": "2026-08-05", "middle_text": "Dividend Alert" } ] }, { "img": "splits.svg", "title": "SPLITS", "msg": "", "data": [ { "txt": "Ajanta Pharma Ltd. has announced <strong>2:5</strong> stock split, ex-date: 20 Mar 15", "dt": "2015-03-20", "middle_text": "Split" } ] }, { "img": "bonus.svg", "title": "BONUS", "msg": "", "data": [ { "txt": "Ajanta Pharma Ltd. has announced <strong>1:2</strong> bonus issue, ex-date: 22 Jun 22", "dt": "2022-06-22", "middle_text": "Bonus Alert" } ] }, { "img": "rights-issues.svg", "title": "RIGHTS", "msg": "No <strong>Rights</strong> history available", "data": [] } ] }

Key Events This Week

07 Sep: Downgrade to Hold amid mixed technical and valuation signals

07 Sep: Technical momentum shifts from bullish to mildly bullish

08 Sep: Technical momentum upgrades to bullish with strong returns

10 Sep: Upgrade to Buy following robust financial and technical performance

Week Open

Rs.3,464.45

Week C...

Read full news article

Ajanta Pharma Upgraded to Buy on Strong Technical and Financial Performance

2026-09-10 08:08:53

Ajanta Pharma Ltd., a mid-cap player in the Pharmaceuticals & Biotechnology sector, has seen its investment rating upgraded from Hold to Buy by MarketsMOJO as of 09 Sep 2026. This upgrade reflects a comprehensive reassessment across four key parameters: Quality, Valuation, Financial Trend, and Technicals, driven by the company’s recent robust financial performance and improving technical indicators.

Read full news article

Ajanta Pharma Ltd. Technical Momentum Shifts to Bullish Amid Strong Returns

2026-09-08 08:00:49

Ajanta Pharma Ltd., a mid-cap player in the Pharmaceuticals & Biotechnology sector, has witnessed a notable shift in its technical momentum, moving from mildly bullish to a more confident bullish stance. This change is underscored by a combination of positive signals from key technical indicators such as MACD, moving averages, and Bollinger Bands, despite mixed short-term price returns relative to the broader Sensex index.

Read full news article

Ajanta Pharma Downgraded to Hold Amid Mixed Technical and Valuation Signals

2026-09-07 08:07:16

Ajanta Pharma Ltd., a prominent player in the Pharmaceuticals & Biotechnology sector, has seen its investment rating downgraded from Buy to Hold as of 4 September 2026. This adjustment reflects a nuanced reassessment across four key parameters: quality, valuation, financial trend, and technical indicators. Despite strong recent financial results and long-term outperformance, evolving market dynamics and valuation pressures have tempered investor enthusiasm.

Read full news article

Ajanta Pharma Ltd. Technical Momentum Shifts Amid Mixed Market Signals

2026-09-07 08:00:26

Ajanta Pharma Ltd., a mid-cap player in the Pharmaceuticals & Biotechnology sector, has experienced a subtle shift in its technical momentum, moving from a bullish to a mildly bullish stance. Despite a recent downgrade in its Mojo Grade from Buy to Hold, the stock continues to demonstrate resilience with strong long-term returns, though short-term indicators suggest caution for investors.

Read full news article

Ajanta Pharma Ltd. is Rated Hold by MarketsMOJO

2026-09-05 10:10:16

Ajanta Pharma Ltd. is rated 'Hold' by MarketsMOJO, with this rating last updated on 04 September 2026. While the rating change occurred on that date, the analysis and financial metrics discussed here reflect the stock's current position as of 05 September 2026, providing investors with the most up-to-date view of the company’s performance and outlook.

Read full news article

Ajanta Pharma Ltd. is Rated Buy by MarketsMOJO

2026-08-25 10:11:15

Ajanta Pharma Ltd. is rated 'Buy' by MarketsMOJO, with this rating last updated on 30 July 2026. However, the analysis and financial metrics presented here reflect the stock's current position as of 25 August 2026, providing investors with the most up-to-date insight into the company’s performance and outlook.

Read full news article

Ajanta Pharma Ltd: Valuation Shift Signals Price Attractiveness Amid Strong Returns

2026-08-24 08:00:07

Ajanta Pharma Ltd., a prominent player in the Pharmaceuticals & Biotechnology sector, has recently undergone a notable shift in its valuation parameters, moving from a 'very expensive' to an 'expensive' rating. This change reflects evolving market perceptions amid robust financial performance and relative comparisons with peers, prompting investors to reassess the stock’s price attractiveness in the current mid-cap landscape.

Read full news article